全文获取类型
收费全文 | 7860篇 |
免费 | 1145篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 209篇 |
妇产科学 | 174篇 |
基础医学 | 968篇 |
口腔科学 | 166篇 |
临床医学 | 849篇 |
内科学 | 1706篇 |
皮肤病学 | 99篇 |
神经病学 | 470篇 |
特种医学 | 205篇 |
外科学 | 1198篇 |
综合类 | 282篇 |
一般理论 | 1篇 |
预防医学 | 658篇 |
眼科学 | 305篇 |
药学 | 596篇 |
中国医学 | 144篇 |
肿瘤学 | 914篇 |
出版年
2023年 | 64篇 |
2022年 | 37篇 |
2021年 | 169篇 |
2020年 | 181篇 |
2019年 | 351篇 |
2018年 | 293篇 |
2017年 | 272篇 |
2016年 | 273篇 |
2015年 | 348篇 |
2014年 | 408篇 |
2013年 | 466篇 |
2012年 | 511篇 |
2011年 | 494篇 |
2010年 | 403篇 |
2009年 | 320篇 |
2008年 | 454篇 |
2007年 | 415篇 |
2006年 | 372篇 |
2005年 | 401篇 |
2004年 | 336篇 |
2003年 | 338篇 |
2002年 | 280篇 |
2001年 | 165篇 |
2000年 | 168篇 |
1999年 | 152篇 |
1998年 | 70篇 |
1997年 | 58篇 |
1996年 | 54篇 |
1995年 | 61篇 |
1994年 | 52篇 |
1993年 | 42篇 |
1992年 | 129篇 |
1991年 | 110篇 |
1990年 | 93篇 |
1989年 | 72篇 |
1988年 | 91篇 |
1987年 | 84篇 |
1986年 | 53篇 |
1985年 | 49篇 |
1984年 | 36篇 |
1983年 | 34篇 |
1982年 | 30篇 |
1981年 | 20篇 |
1979年 | 27篇 |
1978年 | 18篇 |
1976年 | 23篇 |
1974年 | 20篇 |
1972年 | 21篇 |
1971年 | 16篇 |
1970年 | 17篇 |
排序方式: 共有9057条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404
Background
Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.Methods
A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.Results
Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.Conclusions
Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting. 相似文献5.
6.
7.
Scott Kizy Ariella M. Altman Schelomo Marmor Jason W. Denbo Eric H. Jensen Todd M. Tuttle Jane Yuet Ching Hui 《Journal of Geriatric Oncology》2019,10(2):322-329
Introduction
The 21-gene recurrence score (RS) (Oncotype Dx, Genomic Health, Redwood City Ca) has not been validated in an older cohort with estrogen receptor (ER)-positive breast cancer. The objective of this study was to evaluate RS validity in a group of older women with ER-positive breast cancer.Methods
Utilizing the Surveillance, Epidemiology, and End Results Program (SEER) database with available RS, we evaluated women with ER-positive breast cancer aged 18–69 and those 70?years of age and older from 2004 to 2014. We utilized multivariable logistic regression models to evaluate factors associated with RS testing as well as a high-risk categorization for those who underwent testing. Survival was analyzed using Kaplan Meier curves and Cox proportional hazard models.Results
We identified 363,876 women aged 18–69?years and 147,107 women aged 70?years and older. A smaller proportion of patients in the older group (8%) underwent RS testing than in the younger group (18%). Of the patients who underwent testing, distribution of RS was similar between groups. High-risk categorization independently predicted a higher likelihood of death for older patients (hazard ratio 1.47, 95% confidence interval 1.15–1.90). Among patients with high-risk RS, chemotherapy was associated with a decreased risk of death in the younger group, but not in the older group.Conclusion
Older women are less likely to receive RS testing, but when tested, older patients have a similar distribution of RS as compared to younger patients. While high-risk categorization in the older cohort was prognostic, chemotherapy was not associated with improved survival. 相似文献8.
9.
Lu Ping Tan Geok Wee Tan Vijaya Mohan Sivanesan Siang Ling Goh Xun Jin Ng Chun Shen Lim Wee Ric Kim Taznim Begam Binti Mohd Mohidin Nor Soleha Mohd Dali Siew Hoon Ong Chun Ying Wong Halimuddin Sawali Yoke Yeow Yap Faridah Hassan Kin Choo Pua Cheng Eng Koay Ching Ching Ng Alan Soo-Beng Khoo the Malaysian Nasopharyngeal Carcinoma Study Group 《International journal of cancer. Journal international du cancer》2020,146(8):2336-2347
Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein–Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling. 相似文献
10.